The page lists 31 projects related to the topic "mycobacterium".
# | |||
---|---|---|---|
1 | EMI-TB | Eliciting Mucosal Immunity to Tuberculosis | 2015 |
2 | Inflammafish | Cross-talk between inflammation and autophagy in tuberculosis | 2016 |
3 | ACPNMR | Structural dynamics of acyl carrier protein complexes through combined solution and solid-state NMR | 2015 |
4 | MDR Tuberculosis | Evolution and success of the multi-drug resistant M. tuberculosis SIT41 (LAM7-TUR) lineage | 2015 |
5 | MtbTransReg | Translational regulation in the persistence and drug susceptibility of Mycobacterium tuberculosis | 2015 |
6 | MYCO TRAPS | New roles for the cytoskeleton in cell-autonomous immunity to mycobacteria | 2016 |
7 | EndoSubvert | Common mechanisms of host membrane trafficking subversion by intracellular pathogens to rupture bacterial containing vacuoles | 2017 |
8 | MYCONEUTROPHILS | Elucidating the involvement of neutrophils in the pathogenesis of tuberculosis using a zebrafish model | 2017 |
9 | bTB-Test | Volatolomics test for the diagnosis of bovine tuberculosis | 2018 |
10 | NovAnI | Indentification and optimisation of novel anti-infective agents using multiple hit-identification strategies | 2018 |
11 | DynaMO_TB | Spatiotemporal regulation of localization and replication of M. tuberculosis in humanmacrophages | 2018 |
12 | NovInDXS | Development of novel inhibitors of the anti-infective target DXS using dynamic combinatorial chemistry (DCC) | 2018 |
13 | BREFMC2017 | Deciphering the function(s) of the C-type lectin DCIR/CLEC4A in tuberculosis | 2018 |
14 | Mtb CoaBC | CoaBC from the Coenzyme A pathway of Mycobacterium tuberculosis as an antimicrobial drug target | 2018 |
15 | NewBorN | Unveiling new B-, N- containing structures through photoredox catalysis | 2018 |
16 | MTBHLAE | Investigation of a novel immune cell type in Tuberculosis: characterization of the specificity, function and pathogen killing ability of T cells restricted by non-classical HLA-E molecules | 2018 |
17 | PHANTOM | Phenotypic screening the host antimicrobial responses towards the eradication of Mycobacterium tubercuosis | 2018 |
18 | MycoRailway | Discovery and molecular investigation of mycobacterial transporters responsible for iron acquisition | 2018 |
19 | AMR-TB | Theoretical and computational investigation of tuberculosis antimicrobial resistance development based on extensive experimental library of mycobacterium strains | 2019 |
20 | ARREST-TB | Accurate, Rapid, Robust and Economical diagnostic technoliogieS for Tuberculosis | 2019 |
21 | ESX-4 T7SS | Structure/function of a prototypic type VII secretion system from a fast-growing pathogenic mycobacteria | 2019 |
22 | deCrYPtion | Decrypting Mycobacterium cytochrome P450 (CYP) physiological functions by testing hypotheses emitted form large-scale comparative genomics analysis | 2019 |
23 | COMBATTB | Comprehensive Mechanisms of Bacterial Antibiotic Tolerance in Mycobacterium Tuberculosis | 2019 |
24 | Lac-TB | Dissecting the impact of Lactate in Tuberculosis | 2020 |
25 | TBNANO | Targeted intracellular delivery of antitubercular agents by functionalized nanocapsules | 2019 |
26 | LEPVORS | Identification and characterization of new drug resistance and host adaptation mechanisms in Mycobacterium leprae | 2019 |
27 | RespiriTB | Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors | 2019 |
28 | RespiriNTM | Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs | 2019 |
29 | TRIC-TB | Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments. | 2019 |
30 | COMBINE | Collaboration for Prevention and Treatment of MDR Bacterial Infections | 2019 |
31 | SpaTime_AnTB | Single-cell spatiotemporal analysis of Mycobacterium tuberculosis responses to antibiotics within host microenvironments | 2020 |